If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
47
results.
Updated on
02/06/2025 [07:23:00]
Absstract of: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Absstract of: US2025172549A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Absstract of: US2025172555A1
The present invention relates to a lateral flow test device capable of detecting the presence or absence of unfolded p53 in a liquid sample, such as a blood sample. Also provided are methods of using such a device for quantitative or qualitative measurement of U-p53 in a liquid sample. Detection of the presence of this analyte in the sample identifies if the subject has a risk to develop Alzheimer's Disease, and also is useful to confirm a diagnosis of Alzheimer's disease.
Absstract of: US2025170124A1
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
Absstract of: US2025163372A1
A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.
Absstract of: WO2025102250A1
A method, system, composition and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on human brain hippocampus spatial transcriptomics. The present invention achieves rapid and efficient early diagnosis and differential diagnosis of AD cognitive disorder by means of one or more of CCK, Neurogranin and PMP2 carried in plasma extracellular vesicles (EVs), thereby achieving high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, having the advantages of rapidness and low cost, and providing a new technical means and method for clinical application of AD cognitive disorder and large-scale screening-related accurate diagnosis work.
Absstract of: US2025163135A1
Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Absstract of: US2025164471A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Absstract of: AU2023308198A1
The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Absstract of: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Absstract of: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Absstract of: WO2025099458A1
The invention relates to methods of determining whether a subject has, or is at risk of developing, a neurodegenerative disorder using ultra-sensitive techniques, in particular a single-molecular array detection method.
Absstract of: WO2025099460A1
The invention relates to calibration standards for use in a single-molecular detection methods, in particular to quantify protein complexes in a sample.
Absstract of: KR20250064344A
본 발명은 알츠하이머병 동물 모델에서 안구 내 알츠하이머 치매 병리 물질의 침착을 평가하는 방법에 관한 것으로, 본 발명의 방법에 따르면, 알츠하이머병 동물 모델의 안구 내 병리 물질(β-아밀로이드 플라크)의 발현을 평가할 수 있는 바, 관련 용도로 유용하게 사용될 수 있다.
Absstract of: WO2025093893A1
The present invention relates to methods of measuring the presence and/or levels of a combination of five biomarkers in a sample, said biomarkers being neurofilament light (NfL) polypeptide, glial fibrillary acidic protein (GFAP), β-Amyloid 1-42 (Aβ1-42), β-Amyloid 1-40 (Aβ1-40), and phosphorylated Tau (p-Tau181, pTau-231 and/or p-Tau217). The methods can be used to predict the subject's risk or likelihood of having and/or developing Alzheimer's disease, thus also provided is a method of predicting a subject's risk or likelihood of having and/or developing Alzheimer's disease, said method comprising measuring the presence of and/or the levels of the combination of five biomarkers. Further provided is a method of prognosing or diagnosing Alzheimer's disease in a subject comprising the methods of measuring the presence of and/or the levels of the combination of five biomarkers, and a method of treating Alzheimer's disease comprising predicting a subject's risk or likelihood of developing or having Alzheimer's disease using the methods of measuring the presence and/or levels of the combination of five biomarkers and administering a treatment if the risk or likelihood exceeds a threshold value.
Absstract of: US2025147049A1
The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.
Absstract of: US2025147041A1
Methods for the detection or quantitation of amyloid beta include detecting amyloid beta or fragments thereof by mass spectrometry. The methods may also include determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). Such methods may include the diagnosis or prognosis of Alzheimer's disease or dementia.
Absstract of: US2025145722A1
Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Absstract of: WO2025095508A1
The present invention relates to a biohybrid robot including an eye/brain organoid, a motor nerve spheroid, and a muscle bundle, and a manufacturing method therefor. The universal biohybrid robot according to the present invention can generate movement of muscle cells by an electrophysiological signal generated in the eye/brain organoid like a human motor system by using light stimulation and a neurotransmitter. It is expected that the present invention can be used in a disease model simulating a signal transmission system of the human body by combining various neurodegenerative diseases, such as Parkinson and Alzheimer's disease models, and eye tumor models in the future, and can be used to manufacture a drug screening platform that leverages the movement of biohybrid robots composed of living tissues.
Absstract of: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Absstract of: WO2025094139A1
This application is directed to detecting presence or quantity of at least two different molecules. A sensor includes a plurality of chambers, a nanowell array electrode, and a circuit board platform. The sensor separates, cleaves, filters, and detects the at least two different molecules selected from the group consisting of Aβ peptides and tau-protein from a sample in the plurality of nanowells. In some embodiments, the presence or quantity of at least three different Aβ peptides is detected, and an effective amount of a therapeutic compound is administrated to treat Alzheimer in a subject in need thereof.
Absstract of: WO2025096789A1
A method of assaying for activity of a protease enzyme corresponding to a disease in a subject includes selectively capturing an extracellular vesicle (EV) from a sample from the subject; contacting the EV after the capturing with a probe molecule, the probe molecule including a peptide, a fluorescent moiety on a first end of the peptide and a quenching moiety on a second end of the peptide to provide a Fluorescence Resonance Energy Transfer (FRET) pair separated by the peptide, the peptide containing a cleavage sequence for the protease enzyme; and measuring a fluorescence of at least the fluorescent moiety after the contacting to indicate a presence or absence of the occurrence of cleavage of the peptide by the protease enzyme.
Absstract of: EP4548992A2
Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Absstract of: EP4549585A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Absstract of: WO2025090763A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
Absstract of: AU2023357033A1
The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.
Absstract of: AU2023406056A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Absstract of: WO2024240079A1
The present invention relates to the technical field of medicines. Disclosed are a detection marker, a diagnostic marker, a use thereof, and a kit. In the present invention, PPP2R5C is used as a detection marker for the preclinical stage of Alzheimer's disease (AD) and as a diagnostic marker for mild cognitive impairment and AD; thus, the problems of detection defects and lack of effective blood biomarkers in lumbar puncture and PET-CT detection methods used in early diagnosis of AD are solved.
Absstract of: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Absstract of: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Absstract of: US2025130246A1
The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.
Absstract of: AU2023294616A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Absstract of: WO2025080894A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
Absstract of: US2025123297A1
Disclosed herein is a newly identified secreted nanoparticle that is morphologically and molecularly distinct from the recently described nanoparticle termed an exomere. The disclosed nanoparticle is referred to herein as a supermere. Both exomeres and supermeres are amembranous in contrast to membrane-enclosed extracellular vesicles (EVs). Supermeres are smaller and morphologically distinct from exomeres. These supermeres contain cargo with diagnostic and therapeutic applications.
Absstract of: US2025123296A1
A level of mouse Aβ1-40 and a level of mouse APP669-711 in a biological sample derived from an AD model mouse are measured by detection of markers including mouse Aβ1-40 and mouse APP669-711; an APP669-711/Aβ1-40 ratio which is a ratio of the level of mouse APP669-711 to the level of mouse Aβ1-40 is calculated; and when the ratio in the AD model mouse is higher than the same ratio in a reference mouse in which cerebral Aβ deposition is absent, it is judged that an amount of cerebral Aβ deposition in the AD model mouse is higher than an amount of cerebral Aβ deposition in the reference mouse.
Absstract of: US2025122570A1
Methods are provided for identifying Alzheimer's disease cells or subjects, based on the methylation status of multiple methylation markers in genomic DNA. Also provided are methods for identifying therapeutic agents for treating Alzheimer's disease by monitoring changes in the methylation status of multiple methylation markers.
Absstract of: AU2023294616A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Absstract of: US2025115952A1
In the field of aptamers, closed sequence solution space libraries for aptamer selection and related methods for selecting aptamers for binding to target molecules. Also, a method of treating a disease or disorder in a subject, including diagnosing, monitoring, or predicting a using at least one aptamer obtained by the closed sequence solution space libraries, and treating the diagnosed subject. Further a specific set of aptamers, which may be used for detection and/or quantification of a target molecule.
Absstract of: WO2025076222A1
Human tau protein phosphorylated at the amino acid, serine 413 (pS413 tau), can serve as a biomarker for tauopathies such as Alzheimer's disease. Detection and quantitation of pS413 tau in a biological sample such as cerebrospinal fluid can be useful in developing therapeutics for certain tauopathies. However, pS413 tau is present in biological samples at very low levels. Thus, the invention provides a highly sensitive assay for the detection and quantitation of pS413 tau in a biological sample comprising a series of steps as described herein.
Absstract of: US2025116035A1
In the field of aptamers, closed sequence solution space libraries for aptamer selection. Also, methods for selecting aptamers for binding to target molecules in which biological samples derived from individuals that differ by phenotype are contacted with the library of aptamers and the aptamer oligonucleotides that bound to the target molecules are covered. Further, methods of treating a disorder or a disease of a subject in which the disorder or disease is diagnosed using the library of aptamers and the subject is treated.
Absstract of: AU2023356443A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Absstract of: US2023349925A1
The present invention addresses the problem of providing: a determination method that can determine, early and with ease, whether or not a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction has occurred, and the severity level of the disease; and a screening method for a therapeutic agent and a prophylactic agent for a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction. The present invention provides a determination method that can determine disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction early and with ease and also can contribute to drug discovery research for these diseases, with a determination method for determining whether or not a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction has occurred, where drebrin A-related proteins (DARPs) serve as indices, and with a screening method for screening a therapeutic agent and prophylactic agent for a disease caused by synaptic dysfunction or a disease accompanied by synaptic dysfunction, where drebrin A-related proteins (DARPs) serve as indices.
Absstract of: EP4535003A1
Provided is a method for analyzing a neurogranin-related peptide capable of suppressing variations in analysis results, and a method for preparing a biological sample containing a neurogranin-related peptide used therein. A method for preparing a sample solution containing a neurogranin-related peptide, the method includes mixing a biological sample containing a neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 or more and 0.700 or less to prepare a sample solution having a final concentration of the organic solvent of 5.0 (v/v)% or more.
Absstract of: MX2020011458A
The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
Absstract of: CN117589996A
The invention relates to a diagnostic use of highly toxic amyloid oligomers. Specifically, the present invention relates to the use of a novel highly toxic amyloid oligomer A beta o * 3F, specifically bound by a 3F antibody, in the cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, as a target for the diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD.
Absstract of: WO2025068747A1
The present invention relates to the field of neurodegenerative diseases detection and diagnosis, in particular to a delivery system comprising bodipy markers, said delivery system consisting of a modified humanized ferritin from Archaeoglobus fulgidus (HumAfFt) and a bodipy fluorescent marker that selectively binds the TAU protein, compositions comprising said delivery system and methods ad uses thereof.
Nº publicación: WO2025068791A1 03/04/2025
Applicant:
DISRUPTIVE TECH ADVANCES IN LIFE SCIENCE S R L SOCIETA BENEFIT IN FORMA ABBREVIATA D TAILS S R L SB [IT]
FONDAZIONE ST ITALIANO DI TECNOLOGIA [IT]
DISRUPTIVE TECHNOLOGICAL ADVANCES IN LIFE SCIENCE S.R.L.- SOCIET\u00C0 BENEFIT, IN FORMA ABBREVIATA, D-TAILS S.R.L. SB,
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
Absstract of: WO2025068791A1
The present invention relates to the field of neurodegenerative diseases detection and diagnosis, in particular to a delivery system comprising bodipy markers, said delivery system consisting of a modified humanized ferritin from Archaeoglobus fulgidus (HumAfFt) and a bodipy fluorescent marker that selectively binds the TAU protein, compositions comprising said delivery system and methods ad uses thereof.
BOPI
Electronic site
